The present invention relates to an activator of the calcineurin subunit Aβ1 isofomi (CnAβ1) or of the C-terminal domain of the calcineurin subunit Aβ1 isofomi (CnAβ1) for the production of a medicament for the modulation of myocardial growth without adversely affecting contractile function.